Abstract
In autoimmune myasthenia gravis (MG), the identification of antibodies and characterization of serological subgroups is of great importance for diagnosis and management of the disease. Our aims were to study the frequency of antibodies against lipoprotein-related protein 4 (LRP4), agrin, and titin using the most recent techniques, and to characterize corresponding clinical features and autoimmune diseases (AID) in 100 MG-patients. The antibody frequencies in the 55 AChR-antibody positive patients were 7% LRP4, 5% agrin, 53% titin, and in the 45 AChR-antibody negative patients 2% MuSK, 2% LRP4, 2% agrin, and 27% titin. LRP4-MG presented late-onset age, mild symptoms, good therapeutic response, and no thymic changes. Agrin-MG showed early onset age, mild-to-severe symptoms, and moderate treatment response. The phenotype of titin-MG depended on AChR-antibodies: AChR-antibody negative patients presented with mostly mild limb muscle weakness, whereas AChR-antibody positive patients showed more frequently severe symptoms, including myasthenic crisis, bulbar predominance, and thymoma. Additional AID were detected in 32% of MG-patients, most frequently Hashimoto’s thyroiditis (21%). Based on our data, we recommend the detection of LRP4-antibodies for at least AChR-antibody negative MG-patients and titin-antibodies for all MG-patients. We propose taking an accurate medical history for typical symptoms of Hashimoto’s thyroiditis in MG-patients.
Similar content being viewed by others
References
Farrugia ME, Vincent A (2010) Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 23:489–495
Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26:1054–1059
Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368
Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126:2304–2311
DeChiara TM, Bowen DC, Valenzuela DM, Simmons MV, Poueymirou WT, Thomas S, Kinetz E, Compton DL, Rojas E, Park JS, Smith C, DiStefano PS, Glass DJ, Burden SJ, Yancopoulos GD (1996) The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85:501–512
Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, Hubbard SR, Dustin ML, Burden SJ (2008) Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135:334–342
Zong Y, Zhang B, Gu S, Lee K, Zhou J, Yao G, Figueiredo D, Perry K, Mei L, Jin R (2012) Structural basis of agrin-LRP4-MuSK signaling. Genes Dev 26:247–258
Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, Jung J, Wu H, Barik A, Yin DM, Xiong WC, Mei L (2013) Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 123:5190–5202
Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69:418–422
Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139–145
Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, Xiong WC, Lisak RP, Tzartos SJ, Mei L (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69:445–451
Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B, Melms A, Kroger S (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259:427–435
Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V, Schaeffer L, Schalke B, Kröger S (2014) Anti-agrin autoantibodies in myasthenia gravis. Neurology 82:1976–1983
Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, Lisak RP, Mei L (2014) Autoantibodies to agrin in myasthenia gravis patients. PLoS One 9:e91816
Cossins J, Belaya K, Zoltowska K, Koneczny I, Maxwell S, Jacobson L, Leite MI, Waters P, Vincent A, Beeson D (2012) The search for new antigenic targets in myasthenia gravis. Ann NY Acad Sci 1275:123–128
Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain 131:1940–1952
Jacob S, Viegas S, Leite MI, Webster R, Cossins J, Kennett R, Hilton-Jones D, Morgan BP, Vincent A (2012) Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 69:994–1001
Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Tzartos SJ (2015) MuSK autoantibodies in myasthenia gravis detected by cell based assay—a multinational study. J Neuroimmunol 284:10–17
Suzuki S, Utsugisawa K, Nagane Y, Suzuki N (2011) Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011:740583
Gallardo E, Martinez-Hernandez E, Titulaer MJ, Huijbers MG, Martinez MA, Ramos A, Querol L, Diaz-Manera J, Rojas-Garcia R, Hayworth CR, Verschuuren JJ, Balice-Gordon R, Dalmau J, Illa I (2014) Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 13:1003–1007
Cortes-Vicente E, Gallardo E, Martinez MA, Diaz-Manera J, Querol L, Rojas-Garcia R, Illa I (2016) Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol 73:1099–1104
Gilhus NE, Nacu A, Andersen JB, Owe JF (2015) Myasthenia gravis and risks for comorbidity. Eur J Neurol 22:17–23
Aarli JA (2008) Myasthenia gravis in the elderly. Ann NY Acad Sci 1132:238–243
Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Ann Thorac Surg 70:327–334
Hayter SM, Cook MC (2012) Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 11:754–765
Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I (2016) Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol 74:295–302
Beck AT, Steer RA, Brown GK (1996) Beck depression inventory-II. Psychological Corporation:b9, San Antonio
Köllner V, Schauenburg H (2012) Psychotherapie im Dialog-Diagnostik und Evaluation. Georg Thieme Verlag
Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Gilhus NE, Casasnovas Pons C, Pitha J, Jakubikova M, Hanisch F, Bogomolovas J, Labeit D, Labeit S, Tzartos SJ (2016) Titin antibodies in “seronegative” myasthenia gravis - A new role for an old antigen. J Neuroimmunol 292:108–115
Keijzers M, Damoiseaux J, Vigneron A, Bodart N, Kessels A, Dingemans AM, Hochstenbag M, Maessen J, De Baets M (2015) Do associated auto-antibodies influence the outcome of myasthenia gravis after thymectomy? Autoimmunity 48:552–555
Evoli A, Iorio R (2015) Characteristics of myasthenia gravis with antibodies to muscle-specific kinase and low-density lipoprotein-related receptor protein 4. Clinical and Experimental Neuroimmunology 6:40–48
Skeie GO, Mygland A, Aarli JA, Gilhus NE (1995) Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 20:99–104
Szczudlik P, Szyluk B, Lipowska M, Ryniewicz B, Kubiszewska J, Dutkiewicz M, Gilhus NE, Kostera-Pruszczyk A (2014) Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand 130:229–233
Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L, Bourquin C, Bach JF, Garchon HJ (2001) Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 58:885–890
Chen XJ, Qiao J, Xiao BG, Lu CZ (2004) The significance of titin antibodies in myasthenia gravis–correlation with thymoma and severity of myasthenia gravis. J Neurol 251:1006–1011
Gautel M, Lakey A, Barlow DP, Holmes Z, Scales S, Leonard K, Labeit S, Mygland A, Gilhus NE, Aarli JA (1993) Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 43:1581–1585
Somnier FE, Engel PJ (2002) The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology 59:92–98
Romi F, Skeie GO, Aarli JA, Gilhus NE (2000) Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 247:369–375
Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology 8:475–490
Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L, Tonali P (1996) Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord 6:155–161
Vincent A, Bowen J, Newsom-Davis J, McConville J (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2:99–106
Zhao G, Wang X, Yu X, Zhang X, Guan Y, Jiang J (2015) Clinical application of clustered-AChR for the detection of SNMG. Sci Rep 5:10193
Devic P, Petiot P, Simonet T, Stojkovic T, Delmont E, Franques J, Magot A, Vial C, Lagrange E, Nicot AS, Risson V, Eymard B, Schaeffer L (2014) Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol 21:130–134
Rodriguez Cruz PM, Al-Hajjar M, Huda S, Jacobson L, Woodhall M, Jayawant S, Buckley C, Hilton-Jones D, Beeson D, Vincent A, Leite MI, Palace J (2015) Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative Myasthenia Gravis. JAMA Neurol 72:642–649
Mao ZF, Yang LX, Mo XA, Qin C, Lai YR, He NY, Li T, Hackett ML (2011) Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci 121:121–129
Kiessling WR, Finke R, Kotulla P, Schleusener H (1982) Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis. Acta Endocrinol (Copenh) 101:41–46
Chen YL, Yeh JH, Chiu HC (2013) Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol Scand 127:170–174
Kanazawa M, Shimohata T, Tanaka K, Nishizawa M (2007) Clinical features of patients with myasthenia gravis associated with autoimmune diseases. Eur J Neurol 14:1403–1404
Mistry N, Wass J, Turner MR (2009) When to consider thyroid dysfunction in the neurology clinic. Pract Neurol 9:145–156
Toth C, McDonald D, Oger J, Brownell K (2006) Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand 114:124–132
Klein R, Marx A, Strobel P, Schalke B, Nix W, Willcox N (2013) Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol 74:1184–1193
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533
Acknowledgements
We thank the patients and their families for participating in our study. We are grateful for the technical and administrative personnel of the Department of Neurology and the Institute of Neuropathology of the University Hospital Aachen for their support. K.G.C. received grants of the Deutsche Gesellschaft für Muskelkranke e. V. (DGM). P.V. holds a senior clinical investigatorship of FWO-Vlaanderen. L.M. received Grants of NIH (NIH 1 R01 NS090083-01A1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that they have no conflict of interest.
Ethical standard
This research has received approval from the ethical committee of RWTH Aachen University Hospital. Written consent was obtained from all participants.
Rights and permissions
About this article
Cite this article
Cordts, I., Bodart, N., Hartmann, K. et al. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. J Neurol 264, 1193–1203 (2017). https://doi.org/10.1007/s00415-017-8514-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-017-8514-z